Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Hepatitis Drug

Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

SAN FRANCISCO – Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

Categories / Business, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...